A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to establish the safety profile, determine the maximum
tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the
efficacy of SRA737 in prospectively-selected subjects with genetically-defined tumors that
harbor genomic alterations linked to increased replication stress and that are hypothesized
to be more sensitive to checkpoint kinase 1 (Chk1) inhibition via synthetic lethality.
Specific cancer indications that frequently harbor these genetic mutations will be studied.